Navigation Links
Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults
Date:10/26/2008

- Ninety-six week ARTEMIS data presented at ICAAC -

BRIDGEWATER, N.J., Oct. 26 /PRNewswire/ -- Ninety-six week results presented today from a phase 3, randomized, open-label, ongoing clinical trial showed that 79 percent of treatment-naive HIV-1 infected adults taking PREZISTA(R) 800 mg (two 400 mg tablets) with 100 mg ritonavir (r) once daily reached an undetectable viral load (<50 copies/mL) at week 96, compared with 71 percent of patients taking lopinavir/ritonavir 800 mg/200 mg once daily (or 400 mg/100 mg twice daily), each with a fixed dose of emtricitabine and tenofovir disoproxil fumarate.

Results from the study, known as ARTEMIS, were presented today at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC. ARTEMIS is a 192-week study comparing the efficacy and safety of the protease inhibitors (PIs) PREZISTA/r and lopinavir/r in treatment-naive adults with HIV (those who have never taken HIV medication before). PREZISTA was developed by Tibotec Pharmaceuticals and is marketed in the U.S. by Tibotec Therapeutics, a division of Ortho Biotech Products, L.P.

At 48 weeks, the primary objective of ARTEMIS was reached when PREZISTA/r was demonstrated to be non-inferior to lopinavir/r for virologic response (confirmed HIV RNA < 50 copies/mL). The difference between the treatment arms was not significant at week 48. The pre-planned safety and efficacy analysis at 96 weeks was a secondary endpoint. At 96 weeks, the study showed PREZISTA/r was non-inferior to lopinavir/r for virologic response. The estimated difference in virologic response between the treatment groups was eight percent and was statistically significant (95 percent confidence interval 1.8; 14.7). The 96-week results from ARTEMIS will be submitted to the FDA.

"This study offers the healthcare provider community long-term efficacy and safety data for PREZISTA in treatment-naive adult patients," said Tony Mills, M.D., ART
'/>"/>

SOURCE Tibotec Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
4. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
5. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
6. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... -- Vermillion, Inc. (NASDAQ: VRML ), a multivariate ... has appointed Holly B. Bauzon as Vice ... Bauzon has a proven track record in both increasing ... companies. She has more than 20 years of healthcare ... the position of Director, Lab Services Sales and Managed ...
(Date:8/21/2014)...  eRelevance Corporation ( www.erelevancecorp.com ), a progressive ... has completed integration with Nextech, a popular Electronic ... Dermatology practices. "Integration allows our service ... using Nextech," stated Bob Fabbio , co-founder ... the EMR we are able to automatically target ...
(Date:8/21/2014)... NEW YORK , Aug. 21, 2014  Publicis ... Shannon Hartley , Managing Partner and Healthcare Industry ... of PharmaVoice 100, which recognizes the most inspiring people ... group are leaders in research and development, marketing, technology, ... the agency in 2006 as a partner in its ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Shannon Hartley Shines in PharmaVOICE 100 2
... The AXA Research Fund closed out its first year ... than Euro 13 million to various European research institutions.The purpose ... of major risks in the world by supporting cutting edge ... Euro 100 million over five years, making it a major ...
... Research features from Mayo ClinicROCHESTER, Minn., March 23 ... of Discovery,s Edge, Mayo Clinic,s research magazine. You ... often as you wish. Reprinting is allowed with ... as your editorial policies permit: Visit http://discoverysedge.mayo.edu ...
Cached Medicine Technology:First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008 2First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008 3Discovery's Edge Spring Issue - http://discoverysedge.mayo.edu 2
(Date:8/21/2014)... 2014 Florida Hospital Zephyrhills is ... of the only in the Tampa Bay area ... the Olympus Endoalpha Universal Platform for surgical endoscopy. ... endoscopic specialties, and provides the hospital a standardized ... efficiencies and patient care. Surgical endoscopy systems, through ...
(Date:8/21/2014)... NY (PRWEB) August 21, 2014 Local ... often have larger discounts for specific protection plans, according ... now helping consumers to quote life insurance from local ... , The local agents that appear inside of the ... a fast method of price reviews this year. Adults ...
(Date:8/21/2014)... August 11: – Robin William’s suicide was ... hanging, likely due to long-term depression. , ... Vocal Profiling investigator, appeared on the Joyce Riley Power ... hoping to help people understand why he chose not ... were proposed in terms of BioAcoustic Biology: Using vocal ...
(Date:8/21/2014)... The “Proteomics Market by Technology ... Surface Plasmon Resonance, X-ray Crystallography) - Instruments, Reagents ... and studies the major market drivers, restraints, and ... Rest of the World (RoW) , Browse 138 ... pages and in-depth TOC on “Proteomics Market by ...
(Date:8/21/2014)... 22, 2014 DoudouneCanadienneGoosePasCher.fr, one of the ... has recently unveiled its new selection of Trillium Parkas ... announced that all these fashionable and comfortable items are ... special offer will last until September 01. , ... the new Canada Goose Trillium Parkas for ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Zephyrhills is Elevating Healthcare by Offering the First Olympus Fully-Integrated HD Operating Room in Pasco County 2Health News:Florida Hospital Zephyrhills is Elevating Healthcare by Offering the First Olympus Fully-Integrated HD Operating Room in Pasco County 3Health News:Life Insurance from Local Agents Now Priced Nationally Through Complimentary Tool Online 2Health News:Robin Williams: What he could not bear to face 2Health News:Robin Williams: What he could not bear to face 3Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 5Health News:Fashionable And Comfortable Canada Goose Trillium Parkas For Sale At DoudouneCanadienneGoosePasCher.fr 2
... ... 2009. , ... October 16, 2009 -- Tony Rico has recently been promoted to Senior Vice President of ... promotion was effective September 1, 2009. , , , , ,"This position has ...
... A bioethicist who specializes in moral dilemmas families face ... honored with the first-ever March of Dimes Distinguished Lectureship ... a nationally-recognized pediatrician and ethicist, will deliver his lecture ... the American Society of Bioethics and Humanities, 11th annual ...
... Feature Gena Rowlands , EAST BRUNSWICK, N.J., Oct. 15 ... home to New Jersey to host a celebrity cocktail reception ... will raise money for National MS Society,s New Jersey Metro ... Jersey, where it is estimated that almost 10,000 people have ...
... 15 ResMed Inc. (NYSE: RMD ), announced today that ... the first quarter of fiscal year 2010, ended September 30, 2009. ... p.m. Pacific Time and the Company will host a conference call ... , The conference call is scheduled to begin at 1:30 p.m. ...
... AUSTIN, Texas, Oct. 15 deverus, inc., a ... for background screening companies, announced today that Corporate ... deverus, Verocity 2009 software platform to provide an ... An affiliate of Corporate Research and Investigations (Pvt.) ...
... WASHINGTON, Oct. 15 A National Awareness Campaign to ... Arabia to coincide with international Breast Cancer Awareness month. The campaign ... of the Zahra Breast Cancer Association and wife of the ... , and Princess Rima bint Abdullah bin Abdulaziz. It officially ...
Cached Medicine News:Health News:Jackson & Coker Promotes Tony Rico to Senior VP of Operations 2Health News:March of Dimes Establishes Two New Perinatal Bioethics Awards 2Health News:March of Dimes Establishes Two New Perinatal Bioethics Awards 3Health News:East Brunswick Native Returns Home to Help New Jersey Residents Living with MS 2Health News:ResMed Announces Conference Call and Webcast to Discuss First Quarter 2010 Results 2Health News:deverus(TM) Expands Operations Overseas 2
... Plus Povidone Iodine (PVP-I) Prep ... a 10% Povidone Iodine, USP ... Iodine. Triad Plus Povidone Iodine ... saturated with a 7.5% Povidone ...
Prevail is a fast-acting, effective antimicrobial gel that makes preoperative preps easier. This unique gel formulation comes in a specifically designed, easy to use applicator for excellent flow con...
The new, single-use 26 mL applicator is latex-free, hands-off and sterile to help prevent cross-contamination. The applicator is designed for a smooth delivery of the solution for larger surgical pro...
These simple but effective single-dose, hands-off, ampulized applicators have revolutionized skin preparation in hospitals....
Medicine Products: